Results 31 to 40 of about 408 (149)

Checkpoint inhibitor/interleukin‐based combination therapy of cancer

Cancer Medicine, 2022
Background Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the recent studies showed that such therapeutic modality suffers from low durability and low or no
Keywan Mortezaee, Jamal Majidpoor
doaj   +1 more source

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

Immunology &Cell Biology, Volume 104, Issue 10, Page 996-1014, November‐December 2026.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

A Multimodal Framework to Guide Solid Tumor Indications for Natural Killer Cell‐Based Therapy

European Journal of Immunology, Volume 56, Issue 9, September 2026.
This study integrates immunohistochemical evidence of NK cell infiltration in solid tumors, clinical outcomes of NK cell‐based therapies, and transcriptomic analyses of more than 10,000 TCGA samples. Together, these complementary datasets provide a multimodal framework for prioritizing tumor indications and informing the rational design of future NK ...
L. Chiossone, V. Picant, Q. Barbier, T. A. Fehniger, Eric Vivier   +4 more
wiley   +1 more source

The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors

, 2020
Antibody-cytokine fusion proteins (also called 'immunocytokines') represent an emerging class of biopharmaceutical products, which are being considered for cancer immunotherapy.
De Luca R., Villa A., Nadal L., Neri D., Corbellari R.   +4 more
core   +1 more source

Tissue‐Resident Macrophage in Inflammation and Cancer

MedComm, Volume 7, Issue 9, September 2026.
Opposing macrophage functions in inflammation and cancer converge on shared mechanistic nodes, informing cross‐disease therapeutic strategies. ABSTRACT Tissue‐resident macrophages (TRMs) are long‐lived immune cells strategically distributed across organs, where their functional plasticity enables both homeostatic maintenance and pathological ...
Siyuan Huang, Jiangbo Fan, Wenyi Liu, Di Liu, Rui Wang, Yuanyang Wang, Jianhui Sun, Huacai Zhang, Qingli Cai, Zhe Xu, Fang Xu, Jianxin Jiang, Zhen Wang, Ling Zeng   +13 more
wiley   +1 more source

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

EMBO Molecular Medicine, 2020
Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index.
Leander Huyghe, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uzé, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert, Jan Tavernier   +16 more
doaj   +1 more source

Anti-CD70-IFN-γ immunocytokines bind human CD70.

, 2013
(A) 293T cells were transfected with an expression vector encoding Myc-tagged human CD70 (‘CD70’), or with an empty vector (‘Vec’). 24 h post-transfection, cells were examined for CD70 expression in lysates by anti-Myc immunoblotting (inset, top panel; β-
Peirong Chen (403320), Shoko Nogusa (347948), Heidi Simmons (403323), Gregory P. Adams (269450), Siddharth Balachandran (66976), Calvin Shaller (403322), Suraj Peri (70543), Roshan J. Thapa (403321)   +7 more
core   +1 more source

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment

Immunology &Cell Biology, Volume 104, Issue 7, Page 711-728, August 2026.
Three interconnected processes in glioblastoma (GBM) biology: initiation, stratification, and immunosuppression. 1) Initiation: GBM initiation is proposed to occur through migration of TERT mutation‐bearing neural stem cells from the subventricular zone to the frontal and temporal cortices, where a subsequent oncogenic transformation drives their ...
Emerson Achari, Farah Ahmady‐Nield, Amit Sharma, Ingo G. H. Schmidt‐Wolf, Jarek Maciaczyk, Rodney B. Luwor, Adrian A. Achuthan   +6 more
wiley   +1 more source

Quantitative Mass Spectrometry‐Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio‐Biodistribution

Advanced Science, Volume 13, Issue 38, 9 July 2026.
Monoclonal antibodies are powerful anticancer therapeutics targeting tumor‐associated antigens. Mass spectrometry enables precise and accurate quantification of mAbs in tumor plasma and healthy organs. Unlike ligand binding assay and radioactivity, mass spectrometry does not suffer from matrix effects and labelling artefacts while facilitating method ...
Domenico Ravazza, Sheila Dakhel Plaza, Samuele Cazzamalli, Andrea Ciamarone, Andrea Galbiati, Riccardo Stucchi, Frederik Peissert, Emanuele Puca, Dario Neri, Ettore Gilardoni   +9 more
wiley   +1 more source

Modulation of T-cell responses to Murine Melanoma by Targeted-Cytokine Therapy. [PDF]

, 2001
The present thesis describes the characterization of T cell responses to melanoma and its modulation by in situ cytokine therapy. Previous studies have shown that antibody cytokine fusion proteins, designated immunocytokines, achieve high cytokine ...
Becker, Jürgen C.
core   +1 more source